We are no longer accepting new cases.

Weitz & Luxenberg is accepting cases from arthritis and ulcerative colitis patients who have been taking Xeljanz (tofacitinib) or Xeljanz XR and have experienced deep vein thrombosis (DVT) or pulmonary embolism (PE) blood clots after taking the medication.  

Xeljanz and Xeljanz XR are manufactured by Pfizer and were approved with indications to treat specific adult populations with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ulcerative colitis (UC). A recent clinical trial found that rheumatoid arthritis (RA) patients taking Xeljanz 10 mg twice per day showed increased risks of pulmonary embolism and higher rates of death than patients in the control group. The FDA had not approved “this 10 mg twice daily dose for RA; this dose is only approved in the dosing regimen for patients with ulcerative colitis.”  The study was allowed to continue, but only at the lower approved 5 mg dosage.

Pfizer recently announced they are transitioning rheumatoid arthritis (RA) patients in the study to the lower Xeljanz 5 mg dosage for the remainder of the study period.

FDA has alerted physicians and the public about an increased risk of blood clots in the lungs and death from taking 10 mg twice daily Xeljanz or Xeljanz XR in rheumatoid arthritis (RA) patients. Xeljanz and Xeljanz XR do not contain any warnings about risks of venous thromboembolic events (VTE) such as PE or DVT at present.

The FDA advises patients should not stop or change their dose of Xeljanz or Xeljanz XR without first talking to your health care professional, as doing so may worsen your condition.

Symptoms and Injuries

Patients who are having a venous thromboembolic event (VTE) like a DVT (a deep vein blood clot usually in the legs) or a PE (a blood clot in the lungs) may experience the following symptoms:

  • Sudden shortness of breath or difficulty breathing.
  • Chest or back pain.
  • Coughing up blood.
  • Excessive sweating.
  • Clammy or bluish colored skin.
  • Leg pain including cramping or soreness.
  • Red or discolored skin on the leg.
  • A feeling of warmth in the affected leg.

Any of the above symptoms could be a sign of a dangerous – and even deadly – venous thromboembolic event like a DVT or PE. In addition, it is possible to have a DVT or PE without any warning symptoms.

W&L Can Help Patients Who Experienced Blood Clots After Taking Xeljanz Arthritis, Colitis Drug

Weitz & Luxenberg’s Drug and Medical Device Litigation Unit is interested in hearing from anyone who experienced a DVT or PE blood clot after taking Xeljanz or Xeljanz XR at any dose for their ulcerative colitis, rheumatoid arthritis, or psoriatic arthritis.

An experienced attorney from Weitz & Luxenberg can help patients explore all legal options and determine if patients and their families could be entitled to compensation for pain and suffering, lost wages, and medical expenses.

W&L’s Drug and Medical Device Litigation Practice Group has secured more than $3.5 billion for clients in medical device and malpractice litigations

For a free consultation, contact Weitz & Luxenberg by phone at or use our online form. The attorneys at W&L are ready to assist you and discuss your legal options.